retatrutide triple agonist weight loss trial Retatrutide, an Amazing Future for Cagrilintide vs Retatrutide Compared |

Doering, C

GLP-1s May Reduce the Risk of Dry AMD by More Than 90 Percent For the new study, researchers followed about 91,000 participants for up to 10 years

Those numbers sound bigger than they are: even after the increase, only about 7 in 1,000 GLP-1 patients per year ended up with a hair loss diagnosis, versus roughly 4 to 5 in 1,000 on the other drugs

TRIUMPH-1 Phase 3 obesity results, May 2026 TRIUMPH-4 and TRIUMPH Phase 3 programme dosing information

Nearly 60% of people achieved at least 25% weight loss, and around 40% lost 30% or more of their body weight

Understanding typical energy patterns during Retatrutide treatment helps you work with your body rather than against it